NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES
In the last decade, significant advances have been made in the treatment of patients with Myelodysplastic Syndromes (MDS). Although best supportive care continues to have an important role in the management of MDS, todate the therapeutic approach is diversified according to IPSS risk group, karyoty...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2010-08-01
|
| Series: | Mediterranean Journal of Hematology and Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.mjhid.org/index.php/mjhid/article/view/177 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850059066262421504 |
|---|---|
| author | Francesco D'Alò Mariangela Greco Marianna Criscuolo Maria Teresa Voso |
| author_facet | Francesco D'Alò Mariangela Greco Marianna Criscuolo Maria Teresa Voso |
| author_sort | Francesco D'Alò |
| collection | DOAJ |
| description | In the last decade, significant advances have been made in the treatment of patients with Myelodysplastic Syndromes (MDS). Although best supportive care continues to have an important role in the management of MDS, todate the therapeutic approach is diversified according to IPSS risk group, karyotype, patient’s age, comorbidities, and compliance.
Hematopoietic growth factors play a major role in lower risk MDS patients, and include high dose erithropoiesis stimulating agents, which were shown to prolong survival, and thrombopoietic receptor agonists. Standard supportive care should also include iron chelating therapy to reduce organ damage related to iron overload in transfusion-dependent patients. Biologic therapies have been introduced in MDS, with lenalidomide, which has been shown to induce transfusion independence in most patients with the 5q- Syndrome. Hypomethylating agents have shown efficacy in INT-2/high risk MDS patients, reducing the risk of leukemic transformation and increasing survival. Other agents under development for the treatment of MDS include histone deacetylase inhibitors, farnesyltransferase inhibitors, clofarabine and ezatiostat. |
| format | Article |
| id | doaj-art-d894a0b69d6b4ce6a8b42c58f8885ebb |
| institution | DOAJ |
| issn | 2035-3006 |
| language | English |
| publishDate | 2010-08-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Mediterranean Journal of Hematology and Infectious Diseases |
| spelling | doaj-art-d894a0b69d6b4ce6a8b42c58f8885ebb2025-08-20T02:50:59ZengPAGEPress PublicationsMediterranean Journal of Hematology and Infectious Diseases2035-30062010-08-0122e2010021e201002110.4084/mjhid.2010.02170NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMESFrancesco D'Alò0Mariangela Greco1Marianna Criscuolo2Maria Teresa Voso3Hematology, Catholic UniversityHematology, Catholic UniversityHematology, Catholic UniversityHematology, Catholic UniversityIn the last decade, significant advances have been made in the treatment of patients with Myelodysplastic Syndromes (MDS). Although best supportive care continues to have an important role in the management of MDS, todate the therapeutic approach is diversified according to IPSS risk group, karyotype, patient’s age, comorbidities, and compliance. Hematopoietic growth factors play a major role in lower risk MDS patients, and include high dose erithropoiesis stimulating agents, which were shown to prolong survival, and thrombopoietic receptor agonists. Standard supportive care should also include iron chelating therapy to reduce organ damage related to iron overload in transfusion-dependent patients. Biologic therapies have been introduced in MDS, with lenalidomide, which has been shown to induce transfusion independence in most patients with the 5q- Syndrome. Hypomethylating agents have shown efficacy in INT-2/high risk MDS patients, reducing the risk of leukemic transformation and increasing survival. Other agents under development for the treatment of MDS include histone deacetylase inhibitors, farnesyltransferase inhibitors, clofarabine and ezatiostat.http://www.mjhid.org/index.php/mjhid/article/view/177Myelodysplastic syndrome |
| spellingShingle | Francesco D'Alò Mariangela Greco Marianna Criscuolo Maria Teresa Voso NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES Mediterranean Journal of Hematology and Infectious Diseases Myelodysplastic syndrome |
| title | NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES |
| title_full | NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES |
| title_fullStr | NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES |
| title_full_unstemmed | NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES |
| title_short | NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES |
| title_sort | new treatments for myelodysplastic syndromes |
| topic | Myelodysplastic syndrome |
| url | http://www.mjhid.org/index.php/mjhid/article/view/177 |
| work_keys_str_mv | AT francescodalo newtreatmentsformyelodysplasticsyndromes AT mariangelagreco newtreatmentsformyelodysplasticsyndromes AT mariannacriscuolo newtreatmentsformyelodysplasticsyndromes AT mariateresavoso newtreatmentsformyelodysplasticsyndromes |